Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain.
Nanomedicine
; 16: 258-266, 2019 02.
Article
en En
| MEDLINE
| ID: mdl-30300748
ABSTRACT
Accumulation of amyloid beta (Aß) peptides in the cerebral vasculature, referred to as cerebral amyloid angiopathy (CAA), is widely observed in Alzheimer's disease (AD) brain and was shown to accelerate cognitive decline. There is no effective method for detecting cerebrovascular amyloid (CVA) and treat CAA. The targeted nanoparticles developed in this study effectively migrated from the blood flow to the vascular endothelium as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. We also improved the stability, and blood-brain barrier (BBB) transcytosis of targeted nanoparticles by coating them with a cationic BBB penetrating peptide (K16ApoE). The K16ApoE-Targeted nanoparticles demonstrated specific targeting of vasculotropic DutchAß40 peptide accumulated in the cerebral vasculature. Moreover, K16ApoE-Targeted nanoparticles demonstrated significantly greater uptake into brain and provided specific MRI contrast to detect brain amyloid plaques.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Encéfalo
/
Imagen por Resonancia Magnética
/
Nanopartículas
/
Enfermedad de Alzheimer
Idioma:
En
Revista:
Nanomedicine
Asunto de la revista:
BIOTECNOLOGIA
Año:
2019
Tipo del documento:
Article